Please assess the completion status of the following clinical trial:

Trial Title: Study of ACE-083 in Patients With Facioscapulohumeral Muscular Dystrophy (FSHD)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 10.0

Eligibility Criteria:
Key Inclusion Criteria:~1. Age ≥ 18 years~2. Genetically confirmed Facioscapulohumeral muscular dystrophy type 1 (FSHD1) or FSHD2 (or a first-degree relative with genetically confirmed FSHD1 or FSHD2) and clinical findings meeting FSHD criteria~3. Part 1 TA cohorts:~   1. 6-minute walk distance (6MWD) ≥ 150 meters (without a brace)~  2. Mild to moderate weakness in left and/or right ankle dorsiflexion~   Part 1 BB cohorts:~   a. Mild to moderate weakness in left and/or right elbow flexion~   Part 2 TA cohorts:~  1. 6MWD ≥ 150 and ≤ 500 meters (without a brace)~  2. Mild to moderate weakness in left and right ankle dorsiflexion~   Part 2 BB cohorts:~   a. Mild to moderate weakness in left and/or right elbow flexion~4. Females of childbearing potential must have negative urine pregnancy test prior to enrollment and use highly effective birth control methods during study participation. Hormonal birth control use must be stable for at least 14 days prior to Day 1. Males must agree to use a condom during any sexual contact with females of childbearing potential while participating in the study even if he has undergone a successful vasectomy.~Key Exclusion Criteria:~1. Current/ active malignancy (e.g., remission less than 5 years duration), with the exception of fully excised or treated basal cell carcinoma, cervical carcinoma in-situ, or ≤ 2 squamous cell carcinomas of the skin~2. Symptomatic cardiopulmonary disease, significant functional impairment, or other co morbidities that in the opinion of the investigator would limit a patient's ability to complete strength and/or functional assessments on study~3. Renal impairment (serum creatinine ≥ 2 times the upper limit of normal,(ULN))~4. Aspartate transaminase (AST) and/or alanine transaminase (ALT) ≥ 3 times ULN~5. Increased risk of bleeding (i.e., due to hemophilia, platelet disorders, or use of any anti-coagulation/platelet modifying therapies up to 2 weeks prior to Study Day 1; low dose aspirin \[≤ 100 mg daily\] is permitted)~6. Major surgery within 4 weeks prior to Study Day 1~7. Chronic systemic corticosteroids (≥ 2 weeks) within 4 weeks before Study Day 1 and for duration of study; intra-articular/topical/inhaled therapeutic or physiologic doses of corticosteroids are permitted~8. Androgens or growth hormone within 6 months before Study Day 1 and for duration of study; topical physiologic androgen replacement is permitted~9. Any condition that would prevent MRI scanning or compromise the ability to obtain a clear and interpretable scan of the TA or BB muscles, as applicable (e.g., pacemaker, knee/hip replacement, or metallic implants)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- ACE-083 (Part 1, Cohort 1a) Tibialis Anterior (TA) 150mg (Type: EXPERIMENTAL): ACE-083 150 mg TA unilaterally, once every 3 weeks for up to 5 doses. Drug: ACE-083 Recombinant fusion protein
- ACE-083 (Part 1, Cohort 2a) Tibialis Anterior (TA) 200mg (Type: EXPERIMENTAL): ACE-083 200 mg TA unilaterally, once every 3 weeks for up to 5 doses. Drug: ACE-083 Recombinant fusion protein
- ACE-083 (Part 1, Cohort 3a) Tibialis Anterior (TA) 200mg (Type: EXPERIMENTAL): ACE-083 200 mg TA bilaterally, once every 3 weeks for up to 5 doses. Drug: ACE-083 Recombinant fusion protein
- ACE-083 (Part 1, Cohort 1b) Biceps Brachii (BB) 150 mg (Type: EXPERIMENTAL): ACE-083 150 mg BB unilaterally, once every 3 weeks for up to 5 doses. Drug: ACE-083 Recombinant fusion protein
- ACE-083 (Part 1, Cohort 2b) Biceps Brachii (BB) 200 mg (Type: EXPERIMENTAL): ACE-083 200 mg BB unilaterally, once every 3 weeks for up to 5 doses. Drug: ACE-083 Recombinant fusion protein
- ACE-083 (Part 1, Cohort 3b) Biceps Brachii (BB) 240 mg (Type: EXPERIMENTAL): ACE-083 240 mg BB unilaterally, once every 3 weeks for up to 5 doses. Drug: ACE-083 Recombinant fusion protein
- Placebo (Part 2, DB-PC) Tibialis Anterior (TA) (Type: PLACEBO_COMPARATOR): Part 2, double-blind (DB) placebo-controlled (PC). Placebo TA bilaterally, once every 3 weeks for up to 9 doses.~Drug: Placebo Normal saline~Afterwards, participants were rolled over into the open-label portion and received ACE-083 240 mg TA bilaterally, once every 3 weeks for up to 8 doses.~Drug: ACE-083 Recombinant fusion protein
- ACE-083 (Part 2, DB-PC) Tibialis Anterior (TA) 240 mg (Type: EXPERIMENTAL): Part 2, double-blind placebo-controlled. ACE-083 240 mg TA bilaterally, once every 3 weeks for up to 9 doses.~Drug: ACE-083 Recombinant fusion protein~Afterwards, participants were rolled over into the open-label portion and received ACE-083 240 mg TA bilaterally, once every 3 weeks for up to 8 doses.~Drug: ACE-083 Recombinant fusion protein
- Placebo (Part 2, DB-PC) Biceps Brachii (BB) (Type: PLACEBO_COMPARATOR): Part 2, double-blind placebo-controlled. Placebo BB bilaterally, once every 3 weeks for up to 9 doses.~Drug: Placebo Normal saline~Afterwards, participants were rolled over into the open-label portion and received ACE-083 240 mg Biceps Brachii (BB) bilaterally, once every 3 weeks for up to 8 doses.~Drug: ACE-083 Recombinant fusion protein
- ACE-083 (Part 2, DB-PC) Biceps Brachii (BB) 240 mg (Type: EXPERIMENTAL): Part 2, double-blind placebo-controlled. ACE-083 240 mg Biceps Brachii (BB) bilaterally, once every 3 weeks for up to 9 doses.~Drug: ACE-083 Recombinant fusion protein~Afterwards, participants were rolled over into the open-label portion and received ACE-083 240 mg Biceps Brachii (BB) bilaterally, once every 3 weeks for up to 8 doses.~Drug: ACE-083 Recombinant fusion protein

Based on this trial design, predict the completion outcome and termination type (if applicable).